DCT
1:18-cv-01940
Pfizer Inc v. Teva Pharma USA Inc
Key Events
Complaint
Table of Contents
complaint Intelligence
I. Executive Summary and Procedural Information
- Parties & Counsel:
- Plaintiff: Pfizer Inc. (Delaware)
- Defendant: Teva Pharmaceuticals USA, Inc. (Delaware)
- Plaintiff's Counsel: Morris, Nichols, Arsht & Tunnell LLP
- Case Identification: 1:18-cv-01940, D. Del., 12/07/2018
- Venue Allegations: Venue is alleged to be proper in the District of Delaware as Defendant is a Delaware corporation and has allegedly committed, and will commit, acts of infringement in the district.
- Core Dispute: Plaintiff alleges that Defendant's filing of an Abbreviated New Drug Application (ANDA) seeking to market a generic version of Plaintiff's Xeljanz XR® product constitutes an act of infringement of a patent covering sustained-release formulations of the drug tofacitinib.
- Technical Context: The technology concerns oral pharmaceutical formulations designed for the once-daily, sustained release of tofacitinib, an inhibitor of Janus kinases (JAKs) used to treat autoimmune diseases like rheumatoid arthritis.
- Key Procedural History: The action arises under the Hatch-Waxman Act, triggered by Defendant's filing of ANDA No. 209813, which included a "Paragraph IV" certification asserting that the patent-in-suit is invalid, unenforceable, and/or will not be infringed by Defendant's proposed generic product.
Case Timeline
| Date | Event |
|---|---|
| 2013-03-16 | U.S. Patent No. 9,937,181 Priority Date |
| 2018-04-10 | U.S. Patent No. 9,937,181 Issue Date |
| 2018-10-30 | Teva sends Notice Letter regarding ANDA filing |
| 2018-12-07 | Complaint Filing Date |
| 2034-03-14 | U.S. Patent No. 9,937,181 Expiration Date |
II. Technology and Patent(s)-in-Suit Analysis
U.S. Patent No. 9,937,181 - "Tofacitinib Oral Sustained Release Dosage Forms"
- Patent Identification: U.S. Patent No. 9,937,181 ("Tofacitinib Oral Sustained Release Dosage Forms"), issued April 10, 2018.
The Invention Explained
- Problem Addressed: The patent describes challenges with developing a once-daily (QD) sustained-release version of tofacitinib to replace the existing twice-daily (BID) immediate-release tablet Compl. ¶13 '181 Patent, col. 2:5-10 It notes that simply prolonging the drug's release duration reduces its bioavailability, and that eliminating the "drug holiday" (a period of low plasma concentration) seen with the BID regimen could compromise the immune system by over-inhibiting Janus kinase (JAK) signaling pathways '181 Patent, col. 2:40-64
- The Patented Solution: The invention is a specific oral sustained-release dosage form, implemented as an osmotic pump tablet, that provides a particular pharmacokinetic profile '181 Patent, abstract This formulation is designed to deliver a therapeutic dose of tofacitinib over a 24-hour period while achieving a specific dissolution rate and maintaining a beneficial "drug holiday," thereby balancing patient convenience, bioavailability, and safety '181 Patent, col. 3:21-68
- Technical Importance: The claimed formulation provides the clinical convenience of once-daily administration while aiming to replicate the specific pharmacokinetic profile, including a therapeutically significant drug-free period, that was established as safe and effective for the original twice-daily product '181 Patent, col. 2:55-64
Key Claims at a Glance
- The complaint asserts at least independent claim 1 of the '181 patent Compl. ¶28
- Independent Claim 1 recites a once-daily pharmaceutical dosage form comprising:
- A core comprising 11 mg of tofacitinib (or a salt equivalent) and an osmagen;
- A semi-permeable membrane coating surrounding the core, which comprises a water-insoluble polymer;
- The dosage form being a sustained release form that delivers tofacitinib "primarily by osmotic pressure";
- The water-insoluble polymer being a "cellulose derivative that sustains release"; and
- The dosage form exhibiting a specific dissolution profile when tested in a defined medium and apparatus.
- The complaint does not explicitly reserve the right to assert dependent claims.
III. The Accused Instrumentality
Product Identification
- The accused instrumentality is Defendant Teva's proposed generic tofacitinib extended-release tablets (11 mg), for which it filed ANDA No. 209813 Compl. ¶2 Compl. ¶20
Functionality and Market Context
- The complaint alleges that Teva's product is a generic copy of Pfizer's Xeljanz XR®, an extended-release tablet formulated for once-daily administration Compl. ¶2 Compl. ¶13 Xeljanz XR's active ingredient is tofacitinib citrate, an inhibitor of Janus kinases (JAKs) indicated for the treatment of rheumatoid arthritis Compl. ¶14
- The central act of infringement alleged is the filing of the ANDA itself, which seeks FDA approval to market the generic product prior to the expiration of the '181 patent Compl. ¶28 The complaint states that upon information and belief, if the ANDA is approved, Teva will market and distribute the generic tablets in Delaware and throughout the United States Compl. ¶9
No probative visual evidence provided in complaint.
IV. Analysis of Infringement Allegations
The complaint alleges that Teva's filing of ANDA No. 209813 for a generic version of Xeljanz XR® is a technical act of infringement of at least claim 1 of the '181 patent under 35 U.S.C. § 271(e)(2)(A) Compl. ¶28 The complaint does not provide a detailed claim chart or specific factual allegations mapping Teva's product to the claim elements, but relies on the assertion that Teva is seeking to market a generic copy of the branded product covered by the patent.
'181 Patent Infringement Allegations
| Claim Element (from Independent Claim 1) | Alleged Infringing Functionality | Complaint Citation | Patent Citation |
|---|---|---|---|
| A once daily pharmaceutical dosage form comprising a core comprising 11 mg of tofacitinib, or an equivalent amount of tofacitinib in the form of a pharmaceutically acceptable salt thereof, and an osmagen | The complaint alleges Teva's ANDA product is a generic copy of Xeljanz XR® 11 mg extended release tablets, which necessarily contains the claimed core. | ¶2; ¶22; ¶28 | col. 45:40-50 |
| and a semi-permeable membrane coating surrounding the core wherein said coating comprises a water-insoluble polymer | The complaint alleges Teva's ANDA product will contain the claimed semi-permeable membrane. | ¶28 | col. 33:35-47 |
| wherein said dosage form is a sustained release dosage form | The complaint alleges Teva's ANDA product is an extended-release tablet for once-daily administration. | ¶2; ¶13 | col. 3:21-24 |
| and when added to a test medium...dissolves not more than 30%...in 1 hour, and not less than 35% and not more than 75%...in 2.5 hours and not less than 75%...in 5 hours | The complaint alleges Teva's ANDA product, as a generic copy, will meet the claimed dissolution profile. | ¶28 | col. 78:1-17 |
| and wherein said dosage form delivers the tofacitinib...primarily by osmotic pressure | The complaint alleges Teva's ANDA product will utilize the claimed release mechanism. | ¶28 | col. 20:28-66 |
| and wherein the water-insoluble polymer is a cellulose derivative that sustains release of the tofacitinib | The complaint alleges Teva's ANDA product will use the claimed polymer type. | ¶28 | col. 33:55-65 |
- Identified Points of Contention:
- Scope Questions: A central dispute may concern the definition of "primarily by osmotic pressure." The parties may contest the degree to which the release mechanism must be osmotic versus diffusive or erosional to meet this limitation.
- Technical Questions: A key factual question will be whether Teva's proposed generic product, despite being bioequivalent, meets the specific in-vitro dissolution rate limitations recited in claim 1. While the complaint notes that Teva's Paragraph IV certification materials did not set forth a non-infringement argument Compl. ¶25, this does not preclude Teva from developing one during litigation. The primary dispute, however, is more likely to center on the validity of the patent, as asserted in Teva's Paragraph IV letter Compl. ¶21
V. Key Claim Terms for Construction
- The Term: "primarily by osmotic pressure"
- Context and Importance: This term defines the core release mechanism of the claimed invention. Its interpretation is critical because if Teva's formulation, while achieving a similar release profile, can be shown to operate by a different primary mechanism (e.g., matrix erosion or diffusion), it might support a non-infringement argument. Practitioners may focus on this term to determine if the patent's scope is limited to a specific type of osmotic pump technology described in the specification.
- Intrinsic Evidence for Interpretation:
- Evidence for a Broader Interpretation: The claim language itself does not quantify "primarily," which may suggest it does not require the mechanism to be exclusively or almost exclusively osmotic. A party could argue it means the principal or most significant mechanism among others.
- Evidence for a Narrower Interpretation: The specification extensively describes "osmotic pumps" and "extrudable core systems" that operate via osmotic pressure forcing the drug out of a delivery port '181 Patent, col. 20:28-40 '181 Patent, col. 31:49-65 A party could argue that this focus on specific osmotic pump embodiments limits the term "primarily by osmotic pressure" to these described systems, excluding formulations where other mechanisms like diffusion play a more substantial role.
VI. Other Allegations
- Indirect Infringement: The complaint alleges that Teva intends to "engage in the manufacture, use, offer for sale, sale, and/or importation" of its generic product Compl. ¶30 The prayer for relief also seeks to enjoin Teva from "inducing or contributing to" infringement Compl. Prayer C In the context of an ANDA case, this allegation is prospective, based on the premise that Teva's product labeling would instruct physicians and patients to use the drug for its approved indication, thereby inducing infringement of the asserted claims.
- Willful Infringement: The complaint alleges that "Teva had knowledge of the '181 patent when it submitted ANDA No. 209813" Compl. ¶29 This allegation of pre-suit knowledge, combined with the act of filing the ANDA, forms the basis for a potential willfulness claim. The complaint also seeks a judgment that this is an "exceptional case" under 35 U.S.C. § 285, which allows for the award of attorneys' fees, often in connection with findings of willful infringement Compl. Prayer D
VII. Analyst's Conclusion: Key Questions for the Case
- A core issue will be one of validity: can the '181 patent's claims to a specific dissolution profile and pharmacokinetic outcome for tofacitinib withstand challenges of obviousness? The case may turn on whether combining a known drug (tofacitinib) with a known drug delivery technology (osmotic release tablets) to achieve a particular release profile was an inventive step, especially in light of the specific problems of reduced bioavailability and the need for a "drug holiday" described in the patent.
- A secondary issue will be one of infringement: does Teva's proposed generic formulation, which must be bioequivalent to Xeljanz XR®, also meet every specific structural and functional limitation of claim 1, including the numeric dissolution ranges and the "primarily by osmotic pressure" release mechanism? While the complaint suggests Teva has not articulated a non-infringement defense Compl. ¶25, this remains an open question for the court.
Analysis metadata
Loading Complaint
Suggested improvements